3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
34
Doxorubicin
24
fludarabine phosphate
20
Vinblastine
20
Nivolumab
20
Dacarbazine
20
Brentuximab Vedotin
20
pembrolizumab
19
fludarabine
18
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
14
Filgrastim
13
Melphalan
12
Granulocyte Colony-Stimulating Factor
10
Gemcitabine
10
Bleomycin
10
Tacrolimus
9
Radiotherapy
9
Prednisone
9
Peripheral Blood Stem Cell Transplantation
9
Busulfan
9
Specimen Handling
8
Vincristine
7
Sirolimus
7
Magnetic Resonance Spectroscopy
7
Cyclosporine
7
pegfilgrastim
6
Stem Cell Transplantation
6
Bendamustine Hydrochloride
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
AFM13
×
1 year
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts